Last updated: September 14, 2026
Fluticasone propionate/salmeterol xinafoate is the active combination in GSK’s Advair and Seretide respiratory products. The product generated multibillion-dollar sales before patent expiry, but its commercial position has weakened because of generic competition, payer pressure, and substitution by newer inhaled therapies such as Trelegy Ellipta. The U.S. market now has an FDA-approved generic equivalent, Wixela Inhub, while the originator retains value in brand-loyal, international and device-specific segments.
What is fluticasone propionate and salmeterol xinafoate?
Fluticasone propionate/salmeterol is a fixed-dose inhaled combination of:
- Fluticasone propionate, an inhaled corticosteroid.
- Salmeterol xinafoate, a long-acting beta2-adrenergic agonist.
The combination is approved for maintenance treatment of asthma and chronic obstructive pulmonary disease. It is not indicated for acute bronchospasm.
| Product |
Manufacturer |
Device |
U.S. strengths |
| Advair Diskus |
GSK |
Dry-powder inhaler |
100/50, 250/50, 500/50 mcg |
| Advair HFA |
GSK |
Metered-dose inhaler |
45/21, 115/21, 230/21 mcg |
| Wixela Inhub |
Viatris, formerly Mylan |
Dry-powder inhaler |
100/50, 250/50, 500/50 mcg |
| Seretide |
GSK |
Multiple inhaler formats outside the U.S. |
Country-specific strengths and devices |
The dose notation identifies fluticasone propionate first and salmeterol second. Advair Diskus and Wixela Inhub use the same nominal strength combinations, but their delivery devices are not identical.
What is the FDA regulatory status of Advair and Wixela?
Advair Diskus was approved under NDA 020833, while Advair HFA was approved under NDA 021254. FDA approved Wixela Inhub in January 2019 as the first generic equivalent to Advair Diskus in the United States. The product was developed and commercialized by Mylan, now part of Viatris. [1][2]
Wixela Inhub approval was significant because FDA applied product-specific bioequivalence and device-performance requirements to a complex inhaled product. Approval required evidence that the generic matched the reference product in pharmaceutical performance and drug delivery, not only conventional oral-drug bioequivalence.
FDA product status
| Regulatory issue |
Status |
| Advair Diskus |
Approved reference product |
| Advair HFA |
Approved branded metered-dose product |
| Wixela Inhub |
FDA-approved generic equivalent to Advair Diskus |
| Biosimilar pathway |
Not applicable |
| Substitution |
Dependent on state substitution law, payer policy and product-level listing |
| Acute-rescue indication |
Not approved |
Wixela Inhub is a small-molecule generic, not a biosimilar. The product does not require the biologics licensing pathway used for monoclonal antibodies and other biological products.
When does fluticasone propionate/salmeterol lose exclusivity?
The core market exclusivity for fluticasone propionate/salmeterol has expired in the United States. The commercially important U.S. patent estate covered the active combination, inhaled formulations, dose combinations, delivery systems and manufacturing technology. The principal compound and combination protection dates generally fell in the late 2010s, with some regulatory extensions and patent-term adjustments affecting individual claims.
The practical loss of exclusivity occurred when FDA approved Wixela Inhub in 2019. That event ended Advair Diskus’s effective U.S. monopoly even though individual device, formulation or process patents could remain listed or enforceable for limited periods.
Exclusivity timeline
| Period |
Market event |
| 2000 |
FDA approval of Advair Diskus |
| 2000s |
Advair becomes a major asthma and COPD product |
| 2010s |
Patent litigation and regulatory work on generic dry-powder inhalers |
| 2016-2018 |
Increasing generic and device-related challenges |
| January 2019 |
FDA approves Wixela Inhub |
| 2019 onward |
U.S. generic erosion accelerates |
| 2020s |
Advair remains available, but growth shifts toward newer respiratory products |
The relevant commercial question is no longer whether Advair has basic patent protection. It is whether residual device, formulation, manufacturing or market-access barriers can limit generic substitution. Wixela’s approval demonstrates that those barriers were insufficient to preserve exclusivity for the Diskus product.
What patents protect Advair and Wixela?
The patent estate has historically included several layers:
- Active combination patents covering the use or composition of fluticasone propionate with salmeterol.
- Inhalable powder formulation patents.
- Particle-size and carrier-particle claims.
- Dose-ratio and administration claims.
- Inhaler and blister-packaging claims.
- Manufacturing and delivery-process claims.
- Method-of-use patents for asthma and COPD treatment.
GSK’s patent strategy relied on layered protection rather than one single patent. This structure delayed generic entry but did not prevent it permanently.
How strong is the remaining patent estate?
The estate is weak against a therapeutically equivalent dry-powder generic that has secured FDA approval. It is stronger against:
- Non-identical inhaler designs.
- Alternative particle-engineering methods.
- Manufacturing processes that practice narrow process claims.
- New combinations using the same actives in different devices.
- Certain method-of-use claims outside the scope of the approved generic label.
The commercial strength of a patent is lower than its formal expiration date when a competitor can design around the claim or obtain approval through a different device platform.
Orange Book status
The FDA Orange Book has historically listed patents for Advair products and their delivery systems. Orange Book listings can change as patents expire, delist, or become irrelevant to a particular dosage form. The key distinction is between:
- Patents listed against Advair Diskus.
- Patents listed against Advair HFA.
- Patents covering the drug formulation.
- Patents covering the inhaler device.
- Patents covering approved methods of use.
Wixela Inhub’s approval confirms that the listed and unlisted patent barriers did not block an ANDA-approved dry-powder competitor. The patent position for Advair HFA is separate from the position for Advair Diskus because the products use different delivery systems.
Which companies challenged Advair’s exclusivity?
The most important competitive challenge came from Mylan, which developed Wixela Inhub and obtained FDA approval in 2019. Other generic manufacturers have evaluated or pursued inhaled corticosteroid/long-acting beta agonist combinations, but regulatory approval depends on device-specific equivalence and product design.
The competitive landscape includes:
| Company |
Product or strategy |
Competitive relevance |
| GSK |
Advair Diskus and Advair HFA |
Originator brand |
| Viatris/Mylan |
Wixela Inhub |
First FDA-approved generic equivalent to Advair Diskus |
| Teva |
AirDuo RespiClick and authorized generic versions |
Competes in the same therapeutic class, with a different device and dose structure |
| GSK |
Breo Ellipta and Trelegy Ellipta |
Newer branded respiratory products |
| AstraZeneca |
Symbicort and Breztri |
Competing inhaled maintenance combinations |
| Boehringer Ingelheim |
Stiolto and related products |
Competes in COPD maintenance, with different active ingredients |
AirDuo RespiClick contains fluticasone propionate and salmeterol, but it is not simply a generic version of Advair Diskus. Its device, formulation and approved strengths differ. This distinction limits direct substitution and creates separate regulatory and patent analyses.
What Paragraph IV challenges affected Advair?
Generic applicants commonly use Paragraph IV certifications to assert that listed patents are invalid, unenforceable or not infringed. Advair’s generic-entry process involved patent challenges directed at the combination, formulation and inhaler technology.
The commercial result was more important than any individual litigation claim: FDA approved Wixela Inhub, and the product entered the U.S. market. That outcome indicates that the relevant patent disputes were resolved through litigation outcomes, settlements, claim limitations, design-around strategies or expiration of blocking patents.
A Paragraph IV challenge does not automatically mean immediate generic launch. Launch timing depends on:
- FDA approval.
- Patent expiry.
- Litigation injunctions.
- Settlement terms.
- Regulatory exclusivity.
- Manufacturing readiness.
- Payer and pharmacy contracts.
Publicly reported litigation and settlement terms can differ by product, dosage strength and applicant. The approved Wixela pathway remains the clearest evidence that Advair Diskus was vulnerable to generic competition.
What litigation and settlement issues affect the product?
Advair litigation has focused on the interaction between drug formulation patents and inhaler-device patents. Inhaled products create more complex disputes than conventional tablets because a competitor can match the active ingredients while using a different airflow system, blister arrangement, carrier powder or dose-metering mechanism.
The main litigation risks have involved:
- Whether generic inhaler performance is sufficiently equivalent.
- Whether a generic practices formulation claims.
- Whether device patents cover the competitor’s inhaler architecture.
- Whether a method-of-use claim is infringed by the approved label.
- Whether the asserted patent claims survive validity challenges.
Settlement agreements can delay launch while permitting an agreed entry date. The absence of an announced early-entry date does not mean the originator has permanent protection. Advair’s U.S. history shows that layered litigation postponed but did not prevent competition.
What is the financial trajectory of fluticasone propionate/salmeterol?
Advair was one of GSK’s largest products during the 2000s and early 2010s. Its financial decline began before generic entry because of formulary pressure, patent uncertainty, lower net pricing, and competition from other inhaled therapies.
GSK’s public reporting shows a long-term decline in Advair/Seretide revenue as the product faced U.S. patent erosion and portfolio migration toward newer Ellipta products. Recent GSK reports place greater emphasis on Trelegy, Nucala and other respiratory products, while Advair/Seretide has become an established-product business rather than a growth platform. [3][4]
Financial trajectory
| Phase |
Financial profile |
Main drivers |
| 2000-2010 |
Blockbuster growth and peak profitability |
Broad asthma and COPD adoption, limited generic competition |
| 2011-2015 |
Declining but still high revenue |
U.S. pricing pressure, patent litigation, formulary restrictions |
| 2016-2018 |
Accelerated erosion |
Generic development and migration to newer inhalers |
| 2019-2021 |
Material U.S. decline |
Wixela entry and payer substitution |
| 2022 onward |
Mature, lower-growth brand and generic segment |
Low-cost competition and newer triple therapies |
Advair’s peak annual sales are commonly reported at more than $7 billion globally during its strongest period, although reported totals vary by year, currency and whether the figures include Advair, Seretide and related presentations. GSK no longer relies on the product as a primary growth driver. [3]
Revenue exposure
The largest historical exposure was in the United States, where Advair faced rapid generic substitution after Wixela approval. International markets generally followed different timing because patent terms, regulatory procedures, device substitution rules and reimbursement systems vary by country.
The product still produces revenue through:
- Brand prescriptions where physicians or payers prefer Advair.
- Markets without a directly substitutable generic.
- Generic sales from Viatris and other suppliers.
- Contracted or institutional channels.
- Patients who remain stable on the established device.
Net revenue is more important than prescription volume. A product can retain significant unit demand while losing revenue through rebates, lower list prices and generic substitution.
How does Advair compare with newer respiratory drugs?
Advair is a twice-daily inhaled corticosteroid/long-acting beta agonist combination. Newer products compete through once-daily dosing, triple therapy, device design and stronger positioning in COPD.
| Product |
Components |
Typical positioning |
Competitive effect |
| Advair |
Fluticasone propionate/salmeterol |
Established ICS/LABA |
Price-sensitive mature product |
| Breo Ellipta |
Fluticasone furoate/vilanterol |
Once-daily ICS/LABA |
Newer alternative |
| Trelegy Ellipta |
Fluticasone furoate/umeclidinium/vilanterol |
Once-daily triple therapy |
Captures COPD patients needing an added LAMA |
| Symbicort |
Budesonide/formoterol |
ICS/LABA |
Strong asthma and COPD competitor |
| Breztri Aerosphere |
Budesonide/glycopyrrolate/formoterol |
Triple therapy |
Competes in COPD |
| AirDuo RespiClick |
Fluticasone propionate/salmeterol |
Alternative device and presentation |
Directly related active ingredients, not identical to Advair Diskus |
The key commercial shift is from a mature dual-combination product toward once-daily and triple-therapy products. Advair’s lower price can preserve volume, but its strategic role is defensive.
What generic launch risks exist?
Generic launch risk is high for Advair Diskus because Wixela is already approved and commercially established. The principal risks are:
- Continued price compression.
- Formulary exclusion of the branded product.
- Pharmacy-level substitution.
- Loss of physician differentiation.
- Generic supply interruptions that create temporary pricing opportunities.
- Competition from multiple inhaler designs.
- Patient switching difficulties caused by device differences.
Generic entry risk is lower for Advair HFA than for Advair Diskus where fewer direct equivalents are available. That does not eliminate pressure because payers can shift patients to other inhaled combinations with comparable clinical positioning.
What manufacturing and intellectual-property barriers remain?
Manufacturing inhaled powders is technically demanding. Suppliers must control:
- Particle-size distribution.
- Drug uniformity.
- Moisture exposure.
- Powder blending.
- Dose-metering consistency.
- Device resistance and airflow.
- Container-closure performance.
- Stability through the product shelf life.
These barriers can limit the number of reliable suppliers, even after patents expire. They also create regulatory risk because a product may be chemically equivalent but fail device-performance or aerodynamic-particle-size requirements.
Manufacturing complexity supports a degree of generic pricing discipline. It does not restore originator exclusivity once an approved competitor has demonstrated equivalence.
Are biosimilar competitors a risk?
No. Fluticasone propionate and salmeterol xinafoate are chemically defined small molecules. Competitors enter through abbreviated new drug applications or other small-molecule pathways, not biosimilar applications.
The relevant competitive risks are generic inhalers, authorized generics, alternative combination products and newer branded therapies. Manufacturing and device equivalence are more important than biosimilar interchangeability.
What is the outlook for Advair and its active ingredients?
Advair and Seretide should be treated as mature, declining products. The highest-value growth opportunities are in:
- Low-cost generic supply.
- Contract manufacturing.
- Emerging-market expansion.
- Device improvements.
- Reformulated or once-daily combinations.
- COPD products that add a long-acting muscarinic antagonist.
The originator’s remaining commercial value depends on brand recognition, clinical familiarity, device continuity and international pricing. The active ingredients remain clinically relevant, but the original product has limited ability to command premium pricing in markets with generic substitution.
Key Takeaways
- Fluticasone propionate/salmeterol is the active combination in Advair and Seretide.
- GSK’s Advair franchise was a multibillion-dollar product before patent erosion.
- FDA approved Wixela Inhub in January 2019 as a generic equivalent to Advair Diskus.
- The core U.S. exclusivity position has expired; remaining protection is narrower and device- or process-focused.
- Advair HFA and Advair Diskus require separate regulatory and patent analyses.
- The product is exposed to generic substitution, payer pressure and competition from once-daily and triple-therapy inhalers.
- No biosimilar pathway applies because both active ingredients are small molecules.
- GSK’s commercial growth has shifted from Advair toward newer respiratory products, especially Trelegy.
- Manufacturing inhaled powders remains a practical barrier, but it does not prevent approved generic competition.
- The financial outlook is mature to declining, with value concentrated in cost-sensitive and less penetrated markets.
FAQs
Is Wixela Inhub interchangeable with Advair Diskus?
Wixela Inhub is FDA-approved as a generic equivalent to Advair Diskus, but pharmacy substitution depends on state law, payer rules and the specific product designation.
Does Advair HFA have the same generic competition as Advair Diskus?
No. Advair HFA uses a metered-dose inhaler, while Advair Diskus uses a dry-powder device. Their regulatory pathways, patents and substitution dynamics differ.
Is fluticasone propionate/salmeterol still a profitable product?
Yes, but profitability is lower than during the blockbuster period. Generic competition and rebate pressure have reduced originator margins, while manufacturing scale can support generic profitability.
Which product is replacing Advair in COPD treatment?
Trelegy Ellipta is a major successor product within GSK’s respiratory portfolio, particularly for patients needing inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist therapy.
Can a company launch another fluticasone/salmeterol inhaler?
Yes. A company can pursue an abbreviated or alternative regulatory pathway if it satisfies FDA requirements for formulation, device performance, bioequivalence and labeling, while avoiding enforceable patent claims.
References
- U.S. Food and Drug Administration. (2019). FDA approves first generic of Advair Diskus. https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.). Wixela Inhub prescribing information and product approval records. https://www.accessdata.fda.gov
- GSK plc. (Various years). Annual reports and financial results. https://www.gsk.com
- GSK plc. (2024). Annual report 2023. https://www.gsk.com
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda
